1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>Canada

Contentious Pricing Mechanism Adopted In Canada But Only For ‘A Brief Period’

 
• By Neena Brizmohun

Drug companies are unhappy about a new median price test and the exclusion of the Consumer Price Index in the amended interim guidance from the Patented Medicine Prices Review Board

The PMPRB's mandate is to ensure that medicine prices are not excessive in Canada • Source: Shutterstock

Canada’s Patented Medicine Prices Review Board (PMPRB) has adopted an amended interim guidance that includes a controversial pricing mechanism, but has said the guidance would only apply for “a brief period.” The PMPRB is planning to launch a consultation soon about new guidelines, which it said it would approach “with a fresh and open mind.”

The PMPRB, whose mandate is to ensure that medicine prices are not excessive, announced the move on 27 September, after reviewing responses to a consultation on the amended interim guidance

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Canada

More from North America

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

US FDA Legislative Lead Calls For User Fee Reforms As Renewal Talks Near

 
• By Sarah Karlin-Smith

Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.

Smoldering Myeloma Endpoint Questions Carry J&J’s Darzalex Faspro To US FDA AdComm

 
• By Bridget Silverman

The US FDA seeks advice on the clinical meaningfulness of the endpoints of J&J’s AQUILA trial in smoldering multiple myeloma, highlighting the pitfalls of being the first candidate for the precancerous condition.